EP Global Communications, Inc., Announces First Orders for MPDD Medical Device and the Addition of Eric Lee M.D. M.A. to Medical Team

Share Article

Top NYU Anesthesiologist to Join Corey W. Hunter M.D. in Leadership for New EPGL Med

EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK), is pleased to announce that it is receiving first orders for the FDA 510k cleared MPDD medical device, in advance of the worldwide release of the device in 2013. The Company is also pleased to announce that Eric Lee, M.D. M.A. has joined the Company and will oversee further additions to the medical management team and advancement of new medical devices technologies the Company has interest in pursuing.

Eric Lee M.D. M.A. graduated from Yale University and completed medical school at Boston University. He completed his residency in Physical Medicine and Rehabilitation at NYU Langone Medical Center where he has continued with a Pain Medicine fellowship. Dr. Lee is intimately familiar with the MPDD device and used it as a diagnostic tool in a study of using advanced techniques to treat myofascial pain along with Dr. Michel Dubois MD at NYU. Dr. Lee’s professional interests include pain diagnosis and treatment, disorders of the spine, central, and peripheral nervous system, with a special interest in advanced interventional techniques and minimally invasive spinal procedures. “The MPDD has the potential to become a universal and consistently reliable device for numerous physicians to diagnose certain pain syndromes and therefore lead to more efficient and optimum treatments for patients.” says Dr. Lee. EPGL has set the first quarter of 2013 as its planned release time-frame for the MPDD device worldwide.

First advance orders for new MPDD devices are now being received from physicians and the Company is anticipating very strong demand in 2013 after worldwide distribution release. The MPDD devices will initially be marketed under the therapeutic label and later will be marketed under the diagnostic label with an additional FDA 510k. MPDD devices will be priced between $12,000.00 and $20,000.00 depending on the package level of training and education purchased by physicians and health organizations. The Company will market to pain physicians, primary physicians, Internists, sports medicine physicians and physical therapists to name just a few in the significant market for the MPDD device. The MPDD device is only the first of several products which the Company will market in the months and years ahead as the Company is extremely interested in the promising field of bioelectronics and non-opioid treatments of pain.

Shareholders are the most important asset to EPGL Med. The Company is committed to growing significant market capitalization and shareholder returns. To this end, the Company is now taking requisite steps to resume full reporting status and move up to OTCBB in the near future. New financial statements and filings will begin by end of year 2012.

Shareholders can expect additional announcements shortly about additional management personnel, new offices and new name. Please follow us on Twitter @EPGLMed and the new website under construction is http://www.epglmed.com.

About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.

Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeannie Yeitter
EP Global Communications, Inc.
Email >